Cell & Gene Therapy CDMOs — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform

Cell & Gene Therapy manufacturers on CDMO Signal: 105 listed. 14 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Bristol Myers Squibb (CGT Mfg) (in-house manufacturer, Signal Score 87), Novartis (in-house manufacturer, Signal Score 85.4) and City of Hope (T Cell Manufacturing) (academic or national centre, Signal Score 84). Outside that set, higher Signal Scores on this list include Pharmaron (Signal Score 86.9), FUJIFILM Diosynth Biotechnologies (Signal Score 86.7) and Charles River Laboratories (Signal Score 86.3). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Cell & Gene Therapy CDMOs with the most regulatory evidence on file

Novartis
85.4
Basel, Switzerland
17 FDA inspections · 51 EMA/MHRA GMP certs
Last FDA inspection: 2026-06-24 · NAI
See the evidence →
Catalent
76.1
Tampa, FL
24 FDA inspections · 39 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-22 · VAI
Warning letter 2025-11-20
See the evidence →
FUJIFILM Diosynth Biotechnologies
86.7
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
0 FDA inspections · 35 EMA/MHRA GMP certs
Last FDA inspection: None on file
See the evidence →
AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Thermo Fisher Scientific
77.6
Plainville, MA · Alachua, FL · Cambridge, MA
19 FDA inspections · 10 EMA/MHRA GMP certs
Last FDA inspection: 2026-06-30 · NAI
See the evidence →
105
CDMOs tracked
101
Fully scored
33
With FDA records
160
FDA inspections
315
EMA/MHRA GMP certs
8
Warning letters

Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.

For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).

FDA inspection outcomes across these CDMOs: 67 NAI (no action), 88 VAI (voluntary action), 5 OAI (official action). Leading inspection & GMP sites: United States (110), UNITED KINGDOM (64), Denmark (52), Austria (39), Germany (37).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
2
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
3
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
4
KB
Durham, NC · Boulder, CO
Hiring · 97+ open roles
84.1 98.5 2 insp · 1 GMP 2026-04-01 · VAI Limited —
5
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
6
TK
Boston, MA · Zurich, CH
Fully evidenced
Also makes its own products
83.4 100.0 4 insp · 20 GMP 2026-04-10 · NAI — 100 programs
7
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
83.1 99.2 3 insp · 4 GMP 2025-11-25 · NAI Limited —
8
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
9
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
10
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
81.9 98.8 2 insp · 2 GMP 2025-04-28 · VAI — 22 programs
11
LB
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
81.6 100.0 2 insp · 0 GMP 2026-09-18 · NAI — —
12
SC
Prague, Czech Republic
81.6 100.0 0 insp · 5 GMP None on file — —
13
EF
Planegg, DE · San Diego, CA
81.6 100.0 7 insp · 0 GMP 2026-05-15 · NAI — —
14
NW
Vilnius, LT; Waltham (MA), USA
Hiring · 16 open roles
80.8 100.0 0 insp · 8 GMP None on file Available —
15
CF
Les Ulis, FR
80.3 100.0 0 insp · 4 GMP None on file — —
16
SG
Bengaluru, India
Hiring · 4 open roles
80.3 100.0 3 insp · 0 GMP 2025-02-20 · NAI — —
17
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
18
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
19
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
20
BV
Turku, Finland
Hiring · 2 open roles
79.4 99.8 1 insp · 4 GMP 2024-12-19 · VAI — —
21
RC
Edinburgh, UK · Hopkinton, MA
Hiring · 8 open roles
79.3 96.8 1 insp · 1 GMP 2025-01-21 · VAI Available —
22
UM
Boston, MA
78.7 96.7 2 insp · 0 GMP 2025-12-18 · VAI — —
23
GZ
Indianapolis, IN · Lexington, MA
Hiring · 26 open roles
78.1 100.0 1 insp · 0 GMP 2025-08-27 · NAI Available —
24
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
25
NG
Leiden, NL
78.1 100.0 0 insp · 1 GMP None on file — —
26
ET
Jumet, BE
78.1 100.0 0 insp · 4 GMP None on file — —
27
PG
Berlin, DE
78.1 100.0 0 insp · 4 GMP None on file — —
28
CE
Basel, Switzerland
Hiring · 4 open roles
78.1 100.0 0 insp · 1 GMP None on file — —
29
XP
Bristol, United Kingdom
78.1 100.0 0 insp · 1 GMP None on file — —
30
AD
London, United Kingdom
78.1 100.0 0 insp · 2 GMP None on file — —
31
GP
San Diego, CA
78.1 100.0 0 insp · 1 GMP None on file — —
32
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
77.6 93.2 19 insp · 10 GMP 2026-06-30 · NAI Available 2 programs
33
AG2
San Carlos, CA
77.6 98.8 1 insp · 0 GMP 2025-04-18 · VAI — —
34
VG
San Sebastián, Spain
Hiring · 3 open roles
76.8 100.0 0 insp · 4 GMP None on file Available —
35
SY
Stirling, United Kingdom
76.8 100.0 1 insp · 8 GMP 2025-01-31 · NAI — —
36
CY
Toulouse, FR
76.8 100.0 0 insp · 2 GMP None on file — —
37
CN
Luxembourg, LU
76.8 100.0 0 insp · 1 GMP None on file — —
38
HH
London, United Kingdom
76.8 100.0 0 insp · 4 GMP None on file — —
39
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
76.2 100.0 2 insp · 13 GMP 2024-06-17 · NAI Available 7 programs
40
Tampa, FL
Hiring · 311 open roles
76.1 77.3 24 insp · 39 GMP 2026-05-22 · VAI
Warning letter 2025-11-20
— —
41
BC
Bengaluru, India
Hiring · 48 open roles
75.7 93.1 7 insp · 2 GMP 2025-09-03 · VAI — —
42
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
43
MB
Bergisch Gladbach, Germany
Fully evidenced
73.0 100.0 0 insp · 2 GMP None on file — 8 programs
44
Basel, Switzerland
Hiring · 100+ open roles
Fully evidenced
72.8 86.6 11 insp · 8 GMP 2025-09-29 · VAI — 1 program
45
RT
Rome, IT
Fully evidenced
71.1 100.0 0 insp · 4 GMP None on file — 1 program
46
EM
Baltimore, MD
Also makes its own products
66.1 — — None on file — 4 programs
47
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
64.0 — — None on file — —
48
PBI
Pennington, NJ · Nanjing, CN
64.0 — — None on file — —
49
AN
Columbus, OH
63.0 — — None on file Available —
50
RA
Stockholm, Sweden
63.0 — — None on file — —
51
HG
Yokohama, Japan
Also makes its own products
63.0 — — None on file — —
52
SM
Tokyo, JP
Also makes its own products
63.0 — — None on file — —
53
EA
Singapore, Singapore
63.0 — — None on file — —
54
IP
Ahmedabad, India
62.3 68.9 3 insp · 5 GMP 2025-09-16 · OAI
Warning letter 2026-03-30
— —
55
AB
Research Triangle, NC · San Sebastian, ES
Also makes its own products
61.8 — — None on file — 10 programs
56
OB
Hamilton, ON
61.5 — 0 insp · 2 GMP None on file — —
57
GF
Alameda, CA and South San Francisco
61.5 — — None on file Available —
58
FB
Columbus, OH
Hiring · 15 open roles
61.2 — — None on file Expanding 3 programs
59
MA
College Station, TX
59.0 — — None on file Available —
60
VB
Philadelphia, PA
59.0 — — None on file — —
61
MS
Princeton, NJ
59.0 — — None on file — —
62
WB
59.0 — — None on file — —
63
EB
Waltham, MA
Hiring · 8 open roles
59.0 — — None on file — —
64
EX
La Rochelle, France
Hiring · 3 open roles
59.0 — — None on file — —
65
CZ
Cologne, Germany
59.0 — — None on file — —
66
AS
Lake Nona, FL
Hiring · 8 open roles
59.0 — — None on file — —
67
VM
Cambridge, MA
59.0 — — None on file — —
68
AP
Milpitas, CA
59.0 — — None on file — —
69
AM
Gerenzano, Italy
59.0 — — None on file — —
70
HX
Seoul, KR
Also makes its own products
59.0 — — None on file — —
71
CTP
Melbourne, Australia
59.0 — — None on file — —
72
SS
Bloomington, IN
59.0 — — None on file — —
73
PO
San Diego, CA
Hiring · 3 open roles
Also makes its own products
58.7 — — None on file — 6 programs
74
TR
Kusatsu, Shiga Prefecture, Japan
57.9 — — None on file — 8 programs
75
KC
Gainesville, FL · Research Triangle Park, NC
Hiring · 8 open roles
56.5 — — None on file — —
76
UB
Shanghai, CN · Boston, MA
Hiring · 1 open role
56.5 — — None on file — —
77
CV
Cologne, Germany
56.5 — — None on file — —
78
GC
Yongin, KR
56.5 — — None on file — —
79
CH
56.5 — — None on file — —
—
Germany
Profiled — 2 insp · 2 GMP 2023-09-08 · VAI — —
—
Chongqing, China
Profiled — 1 insp · 0 GMP 2024-03-29 · NAI — —
—
Seal Beach, California, United States
Also makes its own products
Profiled — 3 insp · 0 GMP 2025-10-29 · VAI — —
—
San Diego, California, USA
Profiled — — None on file — —
How we score CDMOs →

What to evaluate in a Cell & Gene Therapy CDMO

Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.

Which CDMOs integrate cell therapy processing with viral vector supply?

Integration matters most for ex vivo cell engineering — CAR-T and gene-modified HSC programs — where the vector and the cells need to move through a coordinated chain-of-identity. CDMOs covering both include Lonza (lentiviral + cell therapy at multiple sites), Catalent (AAV + cell therapy through the Paragon and MaSTherCell heritage), Charles River (multi-platform), and Thermo Fisher (viral vector + cell processing). The rankings above surface every CDMO tracked in either category; look for names appearing on both lentiviral and cell therapy filters as your integrated candidate shortlist.

How is cell therapy CDMO scoring different from vector CDMO scoring?

The Signal Score composition is identical, but the underlying signals diverge. Cell therapy CDMOs weight cleanroom infrastructure, chain-of-identity systems, cold-chain and cryopreservation posture, and per-patient batch process discipline. Vector CDMOs weight bioreactor scale, containment (BSL-2 for lentivirus), and analytics maturity. The Quality pillar reflects inspection history on the specific process class — a strong record on cell therapy inspections doesn't automatically de-risk vector manufacturing at the same site. Verify inspection scope at the profile level.

How CDMO Signal aggregates the cell and gene therapy view

This ranking is the union of CDMOs tagged with any viral-vector platform (AAV, lentiviral, adenoviral), any CDMO tagged directly with "gene therapy", and any CDMO tagged with "cell therapy". Each CDMO appears once regardless of how many categories they cover. This is the broadest advanced-therapy candidate list on our platform — for platform-specific filtering, use the dedicated modality pages.

What differentiates an approved-program cell and gene therapy CDMO?

CDMOs that have manufactured for approved cell or gene therapy products — Novartis/Kymriah (BMS Celgene), Gilead/Yescarta, bluebird bio's ex vivo gene therapies, Novartis Zolgensma — carry demonstrable commercial-scale posture. That level of track record is a hard buyer signal that no ranking algorithm captures perfectly; the Signal Score reflects it indirectly through inspection density and clinical footprint. For late-stage programs specifically, cross-reference the CDMO profile page with ClinicalTrials.gov and FDA product approvals for direct evidence.

Cell & Gene Therapy CDMOs — Frequently Asked Questions

Who are the top Cell & Gene Therapy CDMOs?
Among Cell & Gene Therapy manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Bristol Myers Squibb (CGT Mfg), Novartis, City of Hope (T Cell Manufacturing). The table above is the full list. CDMOs cannot pay to change a score.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 33 Cell & Gene Therapy CDMOs with FDA inspection records and 315 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
The table on this page is the live list: the union of cell therapy, AAV, lentiviral, adenoviral, and gene-therapy-tagged manufacturers. This is the broadest advanced-therapy candidate list on the platform. CDMOs cannot pay to change a score.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Cell & Gene Therapy shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Cell Therapy CDMOs AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Viral Vector

For a European shortlist, see the best cell and gene therapy CDMO in Europe.